Supernus Pharmaceuticals Files 8-K
Ticker: SUPN · Form: 8-K · Filed: May 28, 2025 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K, likely routine updates. Monitor for details.
AI Summary
On May 22, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events beyond routine reporting were detailed in the provided excerpt.
Why It Matters
This filing indicates Supernus Pharmaceuticals is providing updates to the SEC, which could include routine disclosures or information about significant corporate events.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification without specific material events or financial disclosures that would indicate immediate risk.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- May 22, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What specific "Other Events" are being reported by Supernus Pharmaceuticals, Inc. in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" beyond listing the item category.
What is the purpose of filing an 8-K form?
An 8-K form is used by publicly traded companies to disclose material events that shareholders should know about.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on May 22, 2025.
What is the principal executive office address for Supernus Pharmaceuticals, Inc.?
The principal executive offices are located at 9715 Key West Ave, Rockville, MD 20850.
What is the SEC file number for Supernus Pharmaceuticals, Inc.?
The SEC file number for Supernus Pharmaceuticals, Inc. is 001-35518.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding SUPERNUS PHARMACEUTICALS, INC. (SUPN).